The DOI matches its Crossref record; the references it cites are not checked yet.
Cardioprotective effect of dexrazoxane during treatment with doxorubicin: A study using low‐dose dobutamine stress echocardiography
Abstract
Aim: To assess the late cardioprotective effect of dexrazoxane associated with doxorubicin during treatment of osteosarcoma by means of low‐dose dobutamine stress echocardiography (LDDSE) in non‐relapsed asymptomatic children and teenagers. Patients and Methods: The study population included 58 patients with osteosarcoma divided in three groups, with equivalent age range, gender proportion and body surface area. Group I (21 patients, 14 males, 15 ± 4 years) was analyzed before chemotherapy and considered the control group; Group II (19 patients, 11 males, 19.7 ± 4 years) was treated with 348.4 ± 18 mg/m 2 of doxorubicin only and Group III (18 patients, 14 male, 16.8 ± 5 years) treated with 396.5 ± 55 mg/m 2 of doxorubicin with dexrazoxane in the ratio 10:1. The patients were submitted to LDDSE (maximal dose 5 µg/kg/min). No major side effects were observed. Heart rate, blood pressure, left ventricular diameters, end systolic wall stress (ESWS), and other diastolic and systolic function indexes were assessed at rest conditions and during LDDSE and compared between the three groups. Results: Group III received a doxorubicin dose significantly greater than Group II (P = 0.001). During LDDSE there were no significant changes in the diastolic function indexes in any of the groups, but there was a significant increase of systolic indexes and a decrease of ESWS in Group III compared to group II. There was no significant difference of any systolic functional parameters between Group I and III. Considering the ejection fraction (EF) at rest or at LDDSE, 13 patients (69.4%) in Group II and 5 patients (27.7%) in Group III were considered to have systolic dysfunction. (P = 0.02). Conclusion: Myocardial response to LDDSE in patients treated with doxorubicin and dexrazoxane was similar to patients without chemotherapy and better than those treated with doxorubicin only, suggesting less cardiotoxicity. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
Cited by 26
Research works printed but not linked: 45
- 10.1056/NEJM199809243391307 · DOI · Paper page
- 10.1200/JCO.1997.15.4.1544 · DOI · Paper page
- 10.1053/ctrv.2000.0175 · DOI
- 10.1002/1097-0142(19830701)52:1<51::AID-CNCR2820520111>3.0.CO;2-# · doi:10.1002/1097-0142(19830701)52:1<51::aid-cncr2820520111>3.0.co;2-#
- 10.2165/00003495-199856030-00009 · DOI
- Hellmann K, 1996, Anthracycline cardiotoxicity prevention by dexrazoxane: Breakthrough of a barrier—sharpens antitumor profile and therapeutic index, J Clin Oncol, 14, 332, 10.1200/JCO.1996.14.2.332 · doi:10.1200/jco.1996.14.2.332
- 10.1200/JCO.1996.14.2.328 · doi:10.1200/jco.1996.14.2.328
- 10.1159/000227621 · DOI
- Stlinhertz LJ, 2001, Cardiac toxicity, 2739
- Fuster V, 1997, Hematology‐oncology and heart disease. Textbook of cardiovascular medicine, 1786
- Steinherz LJ, 1992, Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the Cardiology Committee of thr Chidrens Cancer Study Group, Pediatrics, 89, 942, 10.1542/peds.89.5.942 · DOI · Paper page
- 10.1002/1097-0142(19931101)72:9<2739::AID-CNCR2820720935>3.0.CO;2-R · doi:10.1002/1097-0142(19931101)72:9<2739::aid-cncr2820720935>3.0.co;2-r
- 10.1016/S0002-9149(01)01476-X · doi:10.1016/s0002-9149(01)01476-x
- 10.1016/S0002-9149(00)01222-4 · doi:10.1016/s0002-9149(00)01222-4
- 10.1016/0002-8703(83)90651-8 · DOI
- 10.1016/0140-6736(91)92516-5 · doi:10.1016/0140-6736(91)92516-5
- 10.1016/S0002-8703(97)70205-9 · doi:10.1016/s0002-8703(97)70205-9
- 10.1007/BF02072099 · doi:10.1007/bf02072099
- 10.1016/S0002-8703(99)70468-0 · DOI
- 10.1002/1097-0142(19910715)68:2<435::AID-CNCR2820680237>3.0.CO;2-# · doi:10.1002/1097-0142(19910715)68:2<435::aid-cncr2820680237>3.0.co;2-#
- 10.1016/S0167-5273(97)00114-9 · DOI
- 10.1016/0735-1097(92)90497-B · DOI
- 10.1203/00006450-199603000-00020 · DOI
- 10.1016/S0002-9149(98)00008-3 · doi:10.1016/s0002-9149(98)00008-3
- Lenk MK, 1998, Detection of early anthracycline‐induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography, Turk J Pediatr, 40, 373
- 10.1053/euje.2000.0037 · DOI
- Schwammmasthal E, 1998, Stress echocardiography beyond coronary artery disease, Eur Heart J, 17, D130
- 10.1056/NEJM199506293322602 · DOI · Paper page
- 10.1200/JCO.1998.16.2.545 · doi:10.1200/jco.1998.16.2.545
- 10.1007/BF01954271 · doi:10.1007/bf01954271
- 10.1136/hrt.73.4.340 · doi:10.1136/hrt.73.4.340
- 10.1016/0735-1097(92)90138-D · doi:10.1016/0735-1097(92)90138-d
- 10.1136/hrt.73.1.61 · DOI
- 10.1007/s002469900459 · DOI
- 10.1002/mpo.1135 · DOI
- 10.1016/S0002-9149(99)80254-9 · doi:10.1016/s0002-9149(99)80254-9
- 10.1007/BF02524797 · DOI
- 10.1067/mhj.2000.108237 · DOI
- 10.1016/0002-9149(94)90470-7 · DOI
- 10.1200/JCO.1998.16.1.86 · DOI
- Venturi M, 1996, Multicenter randomized contolled clinical trial to evaluated cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer, J Clin Oncol, 14, 3112, 10.1200/JCO.1996.14.12.3112 · DOI · Paper page
- 10.1200/JCO.1997.15.4.1318 · DOI · Paper page
- 10.1056/NEJM198809223191203 · DOI · Paper page
- 10.1200/JCO.1996.14.2.362 · DOI · Paper page
- 10.1056/NEJMoa035153 · DOI · Paper page
Metadata
- Authors
- Paiva, M. G., Petrilli, A. S., Moisés, V. A., Macedo, C. R. D., Tanaka, C., & Campos, O.
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2005-07-20
- Volume
- 45
- Issue
- 7
- Pages
- 902-908
- ISSN
- 1545-5009
- 1545-5017
- Cited by
- 26
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardioprotective effect of dexrazoxane during treatment with doxorubicin: A study using low‐dose dobutamine stress echocardiography. https://app.cochat.ai/papers/10.1002/pbc.20488
- The paper
- Paiva, M. G., Petrilli, A. S., Moisés, V. A., Macedo, C. R. D., Tanaka, C., & Campos, O. (2005). Cardioprotective effect of dexrazoxane during treatment with doxorubicin: A study using low‐dose dobutamine stress echocardiography. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.20488
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.